HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hill, R. A. Articles by Pell, J. M. Search for Related Content PubMed PubMed Citation Articles by Hill, R. A. Articles by Pell, J. M.

STAYING CURRENT

Antibodies as molecular mimics of biomolecules: roles in understanding physiological functions and mechanisms

¹ Department of Animal and Veterinary Science, University of Idaho, Moscow, Idaho
² Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow
³ The Babraham Institute, Cambridge, United Kingdom

Address for reprint requests and other correspondence: R. A. Hill, Dept. of Animal and Veterinary Science, Univ. of Idaho, PO Box 442330, Moscow, ID. 83844-2330 (e-mail: rodhill{at}uidaho.edu)

Abstract

Physiologists have routinely used understanding of the immune system to generate antibodies against regulatory molecules, growth factors, plasma membrane receptors, and other mammalian molecules in the development of analytical tools and assays. In taking this notion further, antibodies have been used in vivo to modulate physiological systems and to improve our understanding of their molecular interactions. To develop antibodies with physiological activity (efficacy), physiologists have worked with immunologists in developing interdisciplinary insights, requiring basic knowledge of immune system function in designing strategies to generate antibodies that interact with endogenous molecules of physiological interest, in vivo. Antibodies in different physiological systems have been shown to enhance or inhibit endogenous molecular functions. Two approaches have been used: passive and active immunization. Antibodies in these contexts have provided tools to develop further insights into molecular physiological mechanisms. Perhaps surprisingly, enhancing antibodies have been developed against a diverse set of target molecules including several members of the growth hormone/insulin-like growth factor-I axes and those of the β₂-adrenoceptor axis. Antibodies that inhibit the actions of somatostatin have also been developed. A further novel approach has been the development of antibodies that interact with adipose cells in vivo. These have the potential to be used in therapeutic antiobesity approaches. Antibodies with efficacy in vivo have provided new insights into molecular physiological mechanisms, enhancing our understanding of these complex processes.

Key words: growth hormone; insulin-like growth factor-1; somatostatin; β₂-adrenoceptor; adipocyte

WHEN WE THINK about the immune system, we naturally think about its role in fighting disease. The immune system in animals and humans has evolved to form a complex network of biochemical pathways and cellular interactions that are designed to attack, repel, and destroy microorganisms and parasites and their secreted molecules associated with invasion of the body. However, modern technology has enabled us to understand many of these processes, and we are now able to precisely direct immune function against a range of molecules, both naturally produced and completely synthetic. This article addresses the ways in which we have applied our understanding of the immune system to direct some of its actions toward molecules that occur in the body. In this context, antibodies have been used as tools to interact with and modulate the actions of physiological pathways. They have been used to provide knowledge about the mechanisms of action of a range of classes of biomolecules including peptide hormones, receptors, and certain specific cellular targets. This approach to understanding physiological mechanisms involves redirecting immune function to recognize specific "self-antigens" and modulate physiological processes. We will provide examples of how antibodies can be used to inhibit, enhance, or mimic several important physiological processes.

Understanding the Role of the Immune System in Generating Physiologically Active Antibodies
If we assume that it is possible to evoke an immune response against a biomolecule with physiological activity, the technology provides several advantages:

1. The amount of a substance needed to evoke a humoral immune response is very small. Thus, significant antibody production is induced by immunization of animals with as little as 10–50 µg of the active agent. This represents 100- to 10,000-fold less than required for pharmacologically active compounds commonly used in animal studies.
   
2. Because immunization results in a relatively long-lasting response, biological effects may be elicited and studied over an extended period of time.
   
3. Immune modulation provides a tool that may be more specific than pharmacological agents. For example, pharmacological agents developed to recognize one receptor subtype may also interact with additional receptor subtypes, having (undesirable) side effects. Antibodies, which have high specificity, often recognize more discrete molecular domains.
   

We will address the elements required to stimulate an appropriate immune response and consider the ways in which antibodies have been used to both inhibit and stimulate specific molecular axes. Our treatment of the fundamental immunology is not comprehensive. It is designed to provide the reader with the concepts that underlie immune recognition and responses to homologous antigens, a process that is normally actively suppressed to avoid inappropriate autoimmune responses.

Stimulating the immune system to recognize self-proteins.
A key hurdle to be overcome is the ability of the immune system to recognize the self and remain recalcitrant to an autoimmune response when many of the antigens used in this work are self-proteins or domains of self-proteins. Fortunately, our understanding of the cellular and molecular mechanisms that regulate the humoral immune response has been extensively studied in both rodent models and humans, and many of the underlying principals apply or are largely relevant to many species.

Target proteins.
Immune modulation of physiological axes requires antibody recognition (and thus binding) of a target molecule. The characteristics required for a target molecule in vivo are that it must be accessible to the circulatory system and/or extracellular space such that humoral access for molecular interaction is possible, and it must be "immunogenic." In this context, we define "immunogenic" as a molecule that will interact with molecules and cells of the immune system. Thus, target molecules are almost exclusively proteins or peptides and may be hormones/growth factors, specific hormone-binding proteins, hormone receptors, or other cell-associated molecules. In the cases of hormones/growth factors and binding proteins, these are soluble, circulating forms of target proteins, and the primary, secondary, and tertiary structures are usually well described. Thus, there are few problems in identifying suitable domains that may be targeted for antibody recognition.

Directing the immune response.
Our aim is to evoke an immune response in an animal such that the antibodies produced will recognize an endogenous target protein in its native conformation to modulate its activity. Thus, for a hormone, targeting a hydrophobic domain (which is folded to an internal part of the molecule) would be futile. Similarly, for a receptor, targeting an intracellular domain would also be inappropriate. Figure 1 shows the conformation of a receptor subtype that is bound by epinephrine and norepinephrine in vivo, the β₂-adrenoceptor (β₂-AR), and highlights the features of a domain that is a suitable antigen (48). In this example, the antigens were synthetic peptide analogs of an extracellular domain of the native protein. For large molecules such as receptors, the use of a synthetic peptide analog has several advantages: first, a suitable domain may be selected. Using the whole molecule as antigen would produce antibodies that recognize different domains of the receptor, many of which would be unsuitable. Second, a synthetic peptide representing a suitable domain is easily prepared, whereas purification of the receptor to homogeneity is both technically difficult and expensive. This approach has been used successfully in a wide range of examples (7).

View larger version (52K): [in this window] [in a new window]   Fig. 1. Model of the bovine β2-adrenoceptor (β2-AR). This membrane-bound receptor has been the target for a number of studies of immunomodulation (see references). In the study of Hill et al. (48), two synthetic peptide analogs, representing part and all of an outer loop of the β2-AR, were used as antigens to raise antibodies. The larger peptide contained 24 amino acid residues, shown here commencing with His172 (red arrow) through Thr195 (yellow arrow), and the smaller peptide contained 13 amino acid residues, commencing with His172 through Cys184 (green arrow). Although antibodies were raised against both antigens, only antibodies against the longer peptide recognized (and activated) the β2-AR. This illustrates the importance of conformation in antigen design. [From Ref. 89a.]

An antigen is required in more than one form to stimulate antibody production. The antigen needs to contain conformational epitopes that confer configurational specificity, and it also needs to provide T cell epitopes first to activate T helper cells and then to induce T helper cell interactions with antigen-activated B cells.

To enhance this process, when attempting to stimulate B cell recognition and a response against a small peptide antigen (e.g., a hormone or receptor peptide analog), an additional protein is chemically reacted with the target protein. This conjugation of the target protein with another protein is designed to increase the number of T helper epitopes available. There is genetic restriction in the range of T helper epitopes recognized by an individual of any species, and this is related to the major histocompatability complex (MHC) (15). A range of proteins have been characterized for MHC recognition, most thoroughly in the mouse and human. Only relatively few are known for other species. Only class II MHC molecules in the so-called "exogenous pathway" are involved in the humoral response leading to antibody production. Again, we refer the reader to the latest edition of Roitt et al. (89) for greater detail.

Antibody production: the importance of a sustained response.
In the context of generating a clear physiological response, it must be remembered that the active agent is the specific antibody generated by an appropriate immunization protocol. Thus, a central goal of the protocol is to generate antibodies that will be maintained above some unknown but critical blood concentration and to maintain this concentration for the required period of time. One of the great challenges for this technology is to be able to control antibody titers over prolonged periods. Advances in understanding the roles of complex molecular and cellular interactions are building our understanding. The use of specific recombinant cytokines is an example of a fruitful avenue of investigation that will likely lead to more sustained antibody responses (3, 57).

Important Concepts for the Determination of Antibody Action
Antibodies conventionally sequester antigen and inhibit antigen function. However, it is now established that, under specific circumstances, antibodies have the surprising action of potentiating or enhancing peptide hormone activity in vivo. Thus, the strategy for antibody design will depend on the functions of the target molecule and the desired outcome of the study in terms of whether the desired function may be inhibition, potentiation, or some other form of modulation of the target.

Active versus passive immunization.
Two approaches are available for antibody administration: passive or active immunization. In passive immunization, antibodies are generated in a host animal, harvested, and, therefore, may be semipurified and assessed before administration to the target animal, i.e., the target animal is "treated" with defined immunoglobulin and does not need to stimulate its endogenous immune system. These antibodies are cleared from the body over a period of weeks. In active immunization, the target animal is immunized directly with antigen and generates its own antibodies. Three key differences therefore exist between passive and active immunization:

1. Passive immunization may be very controlled (dose and number of treatments), whereas the response to active immunization is less predictable.
   
2. Passive immunization is immediate, but active immunization takes longer as antibodies must be generated (several weeks to months).
   
3. Passive immunization is readily reversible, but active immunization may not reverse for many months. Thus, it is very important to consider the time scale of the target production parameter when designing immunization strategies.
   
4. Passive immunization requires larger amounts of preprepared antibody, whereas active immunization requires minute amounts of antigen.
   
5. Passive immunization carries an increased risk for the host due to potential for reactivity to donor antibodies (anaphylaxis).
   

Control of titer.
As outlined above, maintenance of the antibody dose at an effective titer may be important in achieving a physiological response. In passive immunization, the amount of immunoglobulin administered to the target animal is regulated, and, therefore, titer can be controlled. However, as the immunoglobulin must be injected (usually subcutaneously, intraperitonneally, or infused intravenously), the volume that can be physically administered is restricted, and, therefore, antibody titer in the target animal will be limited. However, the only restriction in active immunization is appropriate stimulation of the immune system, which, in theory, should generate higher titers than by passive strategies. When the target protein is an endogenous peptide or protein, it is necessary to develop strategies for the generation of antibodies against self-molecules [for a review, see Meloen et al. (76)]. Strategies to achieve this goal include conjugation of the endogenous target protein to an immune enhancer, or a carrier molecule. In addition, the immune system is also usually stimulated by presenting the immunogen in an adjuvant, a strategy also used to stimulate the immune response to more usual immunogens. To date, few systematic studies varying the dose of antigen, the nature of the carrier molecule (e.g., ovalbumin, keyhole lympet hemocyanin, or tetanus toxoid), and the immunostimulant (e.g., Freund's complete adjuvant or aluminium hydroxide) have been published. However, responsiveness even to a single-dose combination of these three components may be very variable. For example, anti-placental lactogen antibody titer varied by 10-fold between two subsequent studies that used similar immunization protocols (65). In contrast, even when the dose of antigen has been varied, antibody responsiveness has not (60). Clearly, much work is needed to define immunization strategies. For full optimization, these may be specific for each antigen.

Identifying Important Parameters of Antibody Interactions in Physiological Processes
Importance of antibody affinity.
For this discussion, we will use the example of antibodies raised against IGF-I. IGFs (IGF-I and IGF-II) are important growth factors that are present in high concentrations in the circulation. Their actions are largely influenced by interactions with a family of binding proteins [IGF-binding proteins (IGFBPs)] and associated molecules that may bind IGFs with high affinity (36, 56). Studies of IGF action have extensively evaluated the roles of IGFBPs, especially in the context of the anabolic actions of IGF-I and the physiological responses associated with IGF-IGFBP interactions (90).

Studies of immune modulation of the IGF axis have included both active and passive immunization approaches (10, 44, 45, 47, 49, 50, 58, 62, 72, 73, 83–86, 92, 93, 98, 100) (detailed below). Some of these reports have found an inhibitory effect of specific antibodies on IGF-I actions (58, 62, 98), although many of those cited above have described IGF-I-enhancing activity. One of the factors that has an important influence upon inhibition or enhancement of IGF-I actions is the affinity of the antibody for IGF-I, although other factors, such as the range of epitopes recognized, are also important. When the affinity of the antibody for IGF-I is similar to that of the IGF receptor for IGF-I, there appears to be an IGF-enhancing effect in vivo (44, 45, 84–86, 100) and in vitro (86). In contrast, when the affinity of the antibody for IGF-I is considerably higher than that of the IGF receptor for IGF-I, its actions appear to be inhibitory both in vivo (58, 62) and in vitro (72, 73).

The dynamics of these interactions are complex. If we assume perhaps the simplest model in which there is complete steric hindrance of antibody, IGFBP, and IGF receptor binding to IGF-I, the distribution of bound IGF-I will be proportional to both the affinities of each of these interactions and the concentrations of each of the components (Fig. 2). All of these interactions will be in dynamic equilibrium.

View larger version (7K): [in this window] [in a new window]   Fig. 2. Interactions of IGF-I with antibody (Ab), specific IGF-binding proteins (IGFBPs), and the IGF receptor (IGF-R). The distribution of bound and free IGF-1 depends on the concentration of each of the components and the affinities of each of the interactions. In IGF-I-immunized animals, this system will be in dynamic equilibrium in vivo. As physiological and metabolic changes influence each of the components, shifts in the distribution of each of the components will occur. The size of the font used for each component shows the notional distribution of each component. Thus, there will be little free IGF-1. Although the affinity of the high-affinity binding protein (BP) is much greater than those of the IGF-R and Ab, when the concentrations of the IGF-R and Ab exceed the concentration of IGFBP-3, the distribution of bound IGF-1 among these forms will be similar. In reality, other complex factors modify this simplistic model, which serves to illustrate the relative importance of concentration and affinity. [From Ref. 89a.]

Most peptide hormone receptors have affinities for their ligands in the region of 10^–9–10^–8 M, whereas antibody affinities can vary from as low as 10^–6–10^–10 M. It is generally assumed that antibodies with a higher affinity for the target peptide hormone than its cognate receptor will inhibit the activity of the peptide hormone by effective competition for and sequestration of the peptide ligand. Alternatively, if the antibody has an affinity for the peptide hormone that is equivalent to or less than that of the receptor, then the receptor may be able to compete effectively for the pool of antibody-associated peptide. Furthermore, the pool of available hormone could also be expanded simply because of the presence of a large pool of low-affinity antibody. In this situation, the antibody may appear to be enhancing. Surprisingly, these hypotheses have not been formally tested. However, good analogous examples can be found in the relationship between IGF-I activity and its binding proteins. IGFs are associated with a family of six specific binding proteins (IGFBPs), which can be modified by controlled proteolysis, association with the extracellular matrix or cell membranes, or phosphorylation. In each situation, these modifications can induce changes in the affinity of the IGFBP for IGF-I. High-affinity IGFBPs are inhibitory, whereas low-affinity IGFBPs are potentiating, for IGF-I activity (for a review, see Ref. 56). As outlined above, antibodies that potentiate IGF-I activity in vivo have a modest affinity for IGF-I, similar to that of the IGF type 1 receptor (as discussed in Ref. 100).

Circulating immune complexes.
Even though antibody titers are measured in serum samples, this may not be their only site of action. If the aim of the administered antibody is to inhibit the activity of a circulating physiological regulator, these measurements are appropriate. Similarly, if enhancing antibodies exert their effects simply by prolonging the half-life of the target regulatory molecule, serum titers are most relevant (discussed below). The degree to which these target molecules are complexed to antibodies will depend on their relative concentrations and the affinity of the antibody; however, even relatively low-affinity IGF-I-enhancing antibodies certainly complex IGF-I (100). Immunoglobulins, particularly those of the IgG class, gain access to interstitial and pericellular spaces within tissues (89, 118). Indeed, peripherally administered therapeutic antibodies against amyloid β-peptide are found in the central nervous system (8) and enhancing antibodies to porcine growth hormone (GH) change the distribution of tissue GH (107, 114). An intriguing observation in antibody enhancement of peptide hormone activity is that only a proportion of exogenous hormone needs be complexed to antibody for potentiation to occur (51, 88).

The way in which the immune system deals with circulating immune complexes is also important in our understanding of the efficacy of immune modulation of physiological pathways. After binding to an antigen, an IgG molecule changes conformation, and recognition sites along the molecule, which were previously hidden, become exposed. These sites bind cell-associated proteins expressed by cells of the reticuloendothelial clearance system. (Details of this mechanism are not completely understood, and the reader is referred to Ref. 89 for greater detail.) In the case where IgG is bound to a circulating hormone, the reticuloendothelial clearance system provides an alternative clearance mechanism. Figure 3, from a study by Hill et al. (45), clearly shows that in the presence of specific antibody, the mechanism of clearance of IGF-I was radically shifted from a renal to a hepatic mechanism. Thus, the liver is an organ in which reticuloendothelial clearance is highly active. As stated above, this mechanism is not completely understood and is also affected by factors such as the affinity of the specific IgG for the hormone. Thus, the typical rapid off rates of low-affinity interactions may mean that this mechanism is not highly effective at clearing IgG-bound hormone. Furthermore, the way in which the body handles IgG-bound hormone is very complex, and the mechanism of clearance and affinity of interaction are just two factors.

View larger version (28K): [in this window] [in a new window]   Fig. 3. Clearance of IGF-I from dwarf rats pretreated with sheep anti-IGF-I Ig, nonspecific Ig [nonimmune (NI) Ig], or saline. 125I-labeled IGF-I ([125I]IGF-I) was used in this experiment as a tracer and shows the behavior of endogenous IGF-I. The huge effect of anti-IGF Ig on the clearance mechanism is clear. In the two control groups, the great majority of IGF-I is taken up by the kidneys, degraded, and excreted. In anti-IGF-I Ig-treated rats, much of the IGF-I is complexed with antibody. These "immune complexes" are cleared through the reticuloendothelial system active in the liver. Interestingly, skeletal muscle tended to contain more IGF-I in IGF-I Ig-treated rats, suggesting that this could provide a mechanism for improved muscle growth. [From Ref. 45.]

View larger version (18K): [in this window] [in a new window]   Fig. 4. A: decay curves of IGF-I from plasma of dwarf rats. [125I]IGF-1 was used in this experiment as a tracer and shows the behavior of endogenous IGF-I. Dwarf rats were pretreated with anti-IGF-I Ig (), NI Ig (•), or saline (). B: clearance of IGF-I in dwarf rats pretreated with anti-IGF-I Ig, NI Ig, or saline. Anti-IGF-I treatment reduced the clearance rate of IGF-1, and more IGF-1 remained in the circulation over time. Thus, anti-IGF-I Ig treatment increased the total pool of IGF-1. [From Ref. 45.]

Site of antibody binding to target.
One reason underlying the normally observed inhibitory actions of polyclonal antisera is the multiple binding of antibodies to several sites on the antigen. In terms of peptide hormone action, it is likely that the active site, i.e., the receptor-binding site on the peptide hormone, will be sterically hindered in the presence of specific antibodies, preventing receptor interaction and activation. Even though the sites of binding for all enhancing antisera have not been characterized, all findings to date suggest that enhancing antisera bind to peptide hormones at sites distant from the receptor-binding domain (13, 49, 86, 87). This is shown for IGF-I in Fig. 5. Thus, when designing hormone antigens, it is an advantage if the receptor-binding site is known so that appropriate antigenic peptides can be designed.

View larger version (70K): [in this window] [in a new window]   Fig. 5. The structure of IGF-I, showing the regions that interact with IGFBPs, anti-IGF-I Ig, and the IGF-R from two different perspectives. Residues important for IGFBP interactions (Glu3, Thr4, Gln15, and Phe16), and IGF-R binding (Tyr24, Tyr31, and Tyr60), and the terminal residues (Gly1 and Ala70) are shown by the light gray shading. Residues that have been epitope mapped and interact with growth-enhancing anti-IGF-I Ig (Arg36 to Ile43) are shown by the dark gray shading. This evidence indicates that it may be possible for the antibody to simultaneously bind IGF-I while it is also bound to the receptor or binding proteins. [From Ref. 49.]

MAbs.
An array of exciting new technologies has paved the way for the use of MAbs as tools for passive immunization. MAbs are derived from a single clone and, therefore, generate just one immunoglobulin that defines a single epitope on the antigen, usually conformational rather than to a linear peptide sequence. Thus, a part of the structure of the antigen is accurately mirrored, but this can be very difficult to define by techniques such as epitope scanning (13). A further benefit of MAbs is that their affinity will be precisely known.

A massive advance in MAb technology was the development of genetically engineered antibodies (for reviews, see Refs. 42 and 54). In effect, this means that mouse antibodies can be "engineered" to be identical to the form of those from the "target" species, avoiding counterimmune responses. In theory, antibodies could be engineered for administration to any species. Antibody engineering and phage display techniques thus have huge scope to modify and adapt antibody action, for example, to change the half-life of defined antibody fragments (18), to define minotopes for subsequent active immunization (110), or to change antibody affinity (19). The major impact of this technology has been for therapeutic purposes in humans, for example, for cancer therapy (55, 91), rheumatoid arthritis (23, 108), and anaphylactic shock (43). An important example of a potentially useful therapeutic, humanized MAb was reported by Leckie et al. (64). In this case, a novel anti-IL-5 MAb was administered to human subjects intravenously with the hope of "curing" hyperallergenic responses. The objective was to diminish eosinophilic-associated airway hyperresponsiveness. Both airway (sputum) and blood eosinophils were reduced to very low levels. Despite this encouraging result, airway hyperresponsiveness remained and was, at first, unexplained. Later research indicated that it was likely lung tissue resident eosinophils (which were not accessible to the antibody therapy) and not airway eosinophils that remained and may have still had significant effects on airway responsiveness in asthmatics treated with the antibody. This case points out an important consideration of targeted cell and tissue-specific delivery when attempting to use antibodies as therapeutics.

To date, most "humanized" MAbs have been inhibitory, for example, designed to block TNF- activity in autoimmune disease. However, this technology could be applied to the development of designer antibodies or peptides for the immunological enhancement of hormone activity.

Physiological Effects Using Active Immunization Models
This is the form of immunization with which we are most familiar from everyday life. As children, we are immunized against a range of childhood diseases. In this example, it takes multiple immunizations to confer protective immunity to the child. Protective humoral immunity is only conferred when the blood antibody titer is sufficiently high to neutralize invasion of a pathogenic microorganism. The mechanisms that determine this pattern of response are outlined in Stimulating the immune system to recognize self-proteins. We will not describe the typical immunization strategies that are used, as there are many specific texts that provide this information in detail.

In the case of immunization using a self-protein, again, multiple doses are required. A biological effect is only observed when the titer of the specific antibody is sufficiently high that the antibody concentration is similar to either the circulating concentration of the hormone or, in the case of hormone receptors, sufficiently high that the antibody can interact and either block or activate the receptor in the presence of the cognate hormone. In this respect, hormones are attractive targets as they often circulate in picomolar or even femtomolar concentrations.

One of the issues that makes active immunization problematic is the individual variation in the immune response. Thus, the individual effective dose may be different in each animal in a treatment group. This problem makes interpretation of physiological responses difficult. In Experimental Approaches to Immune Modulation, we provide a discussion of specific examples of immune modulation of physiological axes in animals and the physiological responses achieved.

Experimental Approaches to Immune Modulation
Examples of functional inhibitors of physiological mechanisms.
ANTIBODIES AGAINST SOMATOSTATIN.
Somatostatin (SST) is secreted by a range of tissues, including hypothalamic, gastric, and pancreatic sources. Circulating SST provides a feedback mechanism that downregulates GH secretion by the pituitary gland. As such, SST might be expected to be a target for immunoneutralization to understand the regulation of growth processes in vivo. In fact, SST was one of the earliest hormones studied in this way. Arimura et al. (2) described the blockade of a stress-induced decrease in blood GH by anti-SST in rats. Since then, many studies have been conducted on the underlying mechanism of SST action using antibodies. Early studies in an unselected sheep breed showed large improvements in feed efficiency and growth following immunization against SST (95–97, 99). The mechanism appears to be related to SST action on gut peptides, improving digestion, although in many cases both serum GH and IGF-I concentrations increase following SST immunization. Subsequent studies in sheep that were selected for high growth either failed to show these effects (52) or the effects were smaller (9, 63, 105, 106).

These effects have also been demonstrated in other species including chickens (94) and piglets for which the sow had been SST immunized (32). SST immunization has also improved pregnancy rates in both sheep and pigs (61). Thus, it appears that immunization against SST results in hormone immunoneutralization and its subsequent clearance from the circulation.

OTHER INHIBITORY ANTIBODIES.
A number of strategies have been attempted to invoke antibodies against adrenocorticotrophic hormone or cortisol. The underlying theory of this strategy is that antibodies could be used to neutralize these elements and reduce the effects of stress in animal models (115–117).

There are several examples of immunological intervention for the control of reproduction that have been trialed in livestock. An immunization protocol was developed against gonadotropin-releasing hormone and commercialized in 1990 (53). This strategy has been tested in several species and has been shown to be effective for reversible castration of colts and spaying of fillies (26) and for eliminating boar taint and improving growth performance in boars (28).

Examples of functional enhancers of physiological mechanisms.
GH-RELEASING FACTOR.
GH-releasing factor (GRF) is a 40- to 44-residue peptide that has a role in the stimulation of pituitary GH synthesis and secretion. Therefore, potentiation of its activity could induce increased GH secretion and hence increased GH-stimulated growth. It is known that the receptor-binding region of GRF resides in the NH₂-terminal 29 residues (22). Specific site-directed anti-peptide antibodies were therefore generated against either the NH₂- or COOH-terminal domains of GRF (87); their effects (with and without preincubation with GRF) were examined in vitro (GH release from cultured primary pituitary cells) and in vivo (circulating GH concentrations). Intriguingly, antibodies directed against the NH₂-terminal region of GRF inhibited GRF activity, whereas antibodies directed against the COOH-terminal region enhanced GRF activity. These studies therefore suggest that site of binding of the antibody is indeed important for subsequent hormone activity and that the phenomenon of antibody-mediated enhancement of peptide hormone activity may occur both in vivo and in vitro.

ANTIBODIES AGAINST IGF-I.
Most studies to date have examined the effects of antibodies against IGF-I by passive immunization. Initial studies, using both polyclonal antibodies and MAbs, observed either negligible (58, 98) or short-term inhibitory effects (62) on the growth-promoting activity of IGF-I in vivo. However, subsequent specific antibodies raised against IGF-I in sheep potentiated the ability of IGF-I to stimulate growth in GH-deficient dwarf mice (100). Similar to previous studies, passive administration of anti-IGF-I antibodies increased total circulating IGF-I concentrations.

As IGFs are potent growth factors, their activity is tightly regulated by a family of six high-affinity IGFBPs (for a review, see Ref. 56). The affinity of the enhancing anti-IGF-I antibody reported by Stewart et al. (100) was similar to that of a potentiating IGFBP (2 x 10^–8 M), and, therefore, it was proposed that the antibody in some manner maintained a pool of bioavailable IGF peptide. A subsequent radiotracer study (45) examining IGF-I pharmacokinetics in the presence and absence of enhancing antibodies supported this hypothesis.

As previous investigations into the properties of other peptide hormone-enhancing antibodies have suggested that the site of antibody binding to the peptide is important, the IGF-I epitopes recognized by the enhancing antibody were determined using epitope scanning techniques. In this approach, multiple short and overlapping peptides (typically hexamers or octamers) are synthesized that span the entire sequence of the peptide under investigation; these are then incubated with the antibody, and the sites of interaction are detected by ELISA techniques. The enhancing anti-IGF-I antiserum recognized a very specific region of IGF-I: residues Ser³³ to Cys⁴⁷ (49); moreover, antibodies that did not potentiate IGF-I activity did not recognize this region (86). Interestingly, the domain recognized by the enhancing antibody is situated on the opposite face of IGF-I to the receptor-binding site, consistent with the location of antibodies that potentiate both GH and GRF activities.

ANTIBODIES AS ENHANCERS OF GH ACTIVITY.
The biological function of antibodies is most usually considered as neutralization of antigenic molecules, and, for example, administration of polyclonal antibodies against GH neutralize hormone activity (35, 81). However, certain MAbs were surprisingly shown to increase rather than inhibit GH action, as first demonstrated by Holder et al. (51). This effect upon GH action could be enhanced by precomplexing it with MAbs before administration in an animal model (4, 6). This antibody-mediated enhancement of human GH activity confirmed earlier experiments that had demonstrated the enhancement of EGF, insulin, and other polypeptide hormones by antibodies (for a review, see Ref. 5).

In an attempt to improve the prospects for the development of a peptide vaccination strategy, epitope mapping studies of the GH molecule were undertaken to identify regions of the GH molecule associated with enhancement. Previous GH peptides were principally selected on the basis of computer algorithms that predicted immunogenic regions within the GH molecule. This resulted in the selection of many peptides that were contained in loop structures within the GH molecule and, based on the published crystal structure of GH, were accessible on the surface of the molecule. Antibodies generated from such peptides may be more likely to bind to native protein than those raised against peptides that represent elements of the secondary structure within a protein, and initial epitope mapping studies, using a technique that identifies linear epitopes, showed that polyclonal antibodies raised against bovine GH contained major epitopes that were present in all of the loops joining the four -helixes as well as in the nonordered COOH-terminus of the protein (12). Although many MAbs could not be epitope mapped using this technique, presumably because they recognized discontinuous epitopes, one anti-ovine GH-enhancing antibody, Mab OA15, did bind to a continuous epitope lying between residues 91 and 102 of bovine GH in a loop between helixes 2 and 3 of GH (13). The peptide epitope to which this enhancing Mab bound was used to produce a polyclonal antiserum, and this was shown to be capable of enhancing ovine GH activity in a dwarf mouse model (77).

Most hypotheses regarding the mechanism of enhancement have concentrated on in vivo effects, including increased half-life of the hormone-antibody complex, increased GH receptor occupancy time by hormone-antibody complexes, and targeting of the hormone by the antibody into specific target tissues (e.g., the liver). Evidence has been provided to support some of these hypotheses (75, 107, 113).

ANTIBODIES AGAINST THE GH RECEPTOR AS RECEPTOR AGONISTS.
The concept of identifying the site on a hormone receptor to which the hormone binds and using this to produce antibodies that bind to the same site as the hormone has been explored (Fig. 6). GH activates its receptor [GH receptor (GHR)] by a homodimerization mechanism involving two sites on the hormone molecule interacting with two different receptor proteins, resulting in a 1:2 (hormone-receptor) complex (24). Such a mechanism of GHR interaction suggested that reception activation might be achieved by the binding of appropriate bivalent anti-receptor antibodies to two receptors.

View larger version (30K): [in this window] [in a new window]   Fig. 6. Using anti-receptor antibodies as pseudohormones. The mechanism of action of anti-receptor antibodies is thought to involve antibody binding to extracellular domains of the receptor, not necessarily the hormone-binding site. This principal has been demonstrated for both the growth hormone receptor and for β-ARs. Synthetic peptide mimics of an outer domain of the receptor are used to immunize animals and evoke antibodies that bind to this receptor domain. On antibody binding, a change in the receptor conformation is induced. This leads to an intracellular response using the usual second messenger pathway. [From Ref. 89a.]

ANTIBODIES AS ENHANCERS OF β-AR ACTIONS.
There is an extensive body of research reporting on antibodies raised against elements of the β-AR axis. These include mechanistic and fundamental studies and clinical studies, particularly as there is at least one human idiopathic pathology that appears to be associated with the presence of anti-β-AR antibodies in serum (66, 112). A feature common to many of these studies is that the antibody action can be clearly demonstrated in vitro and in model species. The mechanism appears to be consistent across species and β-AR subtypes and consistent with the proposed underlying theory (outlined in ANTIBODIES AGAINST β-AR LIGANDS).

ANTIBODIES AGAINST β-AR LIGANDS.
Several laboratories have investigated antibodies against β-AR ligands and, subsequently, anti-idiotypic antibodies directed against β-ARs (67). These phenomena were investigated further by a number of groups using MAbs. Following their group's earlier work in rabbits, Chamat et al. (17) raised antibodies in mice to alprenolol-BSA conjugate. Four clones were studied, with reported affinities for alprenolol ranging between 5.3 x 10^–7 and 4.2 x 10^–8 M. Antibodies also showed stereoselectivity, having a higher affinity for the (l)-enantiomer of alprenolol than for the (d)-enantiomer. Guillet et al. (39) then reported a novel method for raising anti-idiotypic MAbs that involved immunizing mice with fixed hybridoma cells bearing a specific antibody for the β-AR. Three anti-idiotypic antibodies were able to bind the β₂-AR. One MAb was capable of generating adenylate cyclase activity, which was inhibited by propranolol, a β-antagonist (40). Fine detail of the nature of the anti-idiotypic response was later reported (16), as was the diversity of V_H and V_L genes encoding the anti-alprenolol antibodies (79). Several review articles by Strosberg and colleagues (67, 101–104) have also described much of this work. None of these studies reported in vivo effects of these antibodies; however, in a later study (60), rats immunized against clenbuterol developed titers, but no biological effects were demonstrated.

ANTIBODIES AGAINST SYNTHETIC PEPTIDE ANALOGS OF β-AR.
Synthetic peptide antigens are only useful if the primary, secondary, and, preferably, tertiary/quaternary structures of the protein in question are known. To attempt to generate peptides corresponding to a (likely) antigenic region of a protein, features such as the position of the sequence on the protein in its native conformation should be considered; i.e., if the sequence occurs on the outer surface of the native protein, or if it forms part of a hydrophilic loop, it is much more likely to be seen by antibodies than a sequence that occurs in a hydrophobic or an internal domain. Fortunately, the β-AR structure has been elucidated. Theveniau et al. (109) raised antibodies in rabbits to two extracellular domains of the hamster β₂-AR. Antibodies recognized the receptor in immunoblots and precipitated radiolabeled β₂-ARs.

In a series of studies, Magnusson et al. (69–71) investigated the occurrence of autoantibodies in patients with idiopathic dilated cardiomyopathy. Because of the limitations of low titers of antibodies in the human serum they studied, anti-peptide antibodies were raised in rabbits and served as a model. The antigens used were 26-amino acid sequences corresponding to outer loop 2 of the β₁-AR and β₂-AR. The main focus of these studies was directed to the β₁-AR as this is the predominant subtype in the heart. Anti-β₁-AR antibodies incubated with C6 glioma cell membranes (rich in β₁-ARs) were able to displace the agonist (isoprenaline) affinity to higher values. However, anti-β₂-AR antibodies did not show any effects on ligand binding when incubated with A431 cell membranes rich in β₂-ARs (68). In a following study (69), β₁- and β₂-peptides were used as antigens in an ELISA to screen the sera of patients with idiopathic dilated cardiomyopathy and from healthy control individuals; 14 of 42 patients and 4 of 34 controls were found to carry antibodies to the β₁-sequence. Only affinity-purified antibodies from ELISA-positive patients had an inhibitory effect on conventional ligand binding to the β₁-AR in C6 glioma cell membranes. These antibodies also recognized the receptor protein in immunoblots and bound in situ to human myocardial tissue. The authors concluded that the antibodies could serve as a marker of an autoimmune response with physiological and/or pathological implications. Another report (70) from this group described the functional effects of antibodies at the β-AR. Rabbits immunized with the β₁-sequence mentioned above developed antibodies that decreased β-antagonist binding in a similar fashion to that described for antibodies from patients with idiopathic dilated cardiomyopathy. Antibodies incubated with transformed Escherichia coli inner membranes (expressing the human β₁-AR) or C6 glioma cell membranes caused a decrease in the number of ligand-binding sites. The decrease was dependent on the concentration of both antibodies and magnesium ions, and antibodies appeared to bind to the receptor with high affinity. Interestingly, the antibodies also produced an agonist-like effect in an in vitro bioassay. Spontaneously beating, isolated neonatal rat cardiomyocytes were incubated with the antibody, which caused a positive chronotropic effect. The effect of the antibodies was blocked by a preincubation with the β₁-peptide and was antagonized by the β₁-selective antagonist bisprolol but not by the β₂-selective antagonist ICI-118,551. This group also investigated the immune response of mice to the analogous β₂-peptide (41) and found that the 26-amino acid peptide induced a T cell-mediated humoral response in three mouse MHC haplotypes. The T cell epitope was located in the NH₂-terminal region of the peptide.

These findings of antibody activity having a biological effect (at the β₁-AR) led another group to study the same mechanism at the β₂-AR. Hill et al. (48) were able to produce anti-β₂-AR antibodies by immunizing rabbits with a similar peptide preparation. These antibodies also had biological activity in bovine smooth muscle, increasing the affinity of a β-antagonist and causing a leftward shift in the concentration-response curve for isoproterenol-induced bovine smooth muscle relaxation. There were a number of possible mechanisms by which the antibodies might exert their effects at the β₂-AR. First, the antibodies might behave similarly to the conventional agonists, by causing a conformational change in the receptor protein upon binding, although the precise sequence of interactions would be different. It has been proposed that conventional agonists bind to side chains of amino acid residues within the cleft formed by the seven transmembrane domains of the receptor (see Fig. 1). However, the mechanism of antibody binding and activation of the β₂-AR is likely to be different. Sterically, antibodies would be precluded from binding to the conventional ligand-binding site deep within the receptor. (The molecular mass of conventional agonists is 1/1,000th that of IgG). Assuming that the antibodies bind to the sequence corresponding to the synthetic peptide used as the antigen, their effects must be mediated via the second outer loop, which joins transmembrane domains 4 and 5 (Fig. 1). Both of these domains play a role in conventional ligand binding. This evidence suggests that the binding of antibodies to outer loop 2 may induce a conformational change in the receptor, analogous to that which follows the binding of a conventional agonist. This proposed conformational change may then lead to receptor activation. This mechanism is consistent with that proposed for the activation of the β₁-AR in human subjects outlined above.

Examples of antiobesity strategies.
ANTIBODIES TO ADIPOCYTE PLASMA MEMBRANES.
Another novel approach to immune regulation of physiological processes is in the use of antibodies in their more classical role of targeting molecules and cells for destruction by the immune system, for example, via complement-mediated cell lysis, but in this case the targeted cells are adipocytes. Antibodies directed against the plasma membranes of adipocytes have been used to induce their destruction and thereby limit the storage capacity for fat. Successful depletion of fat has been achieved in rats, sheep, and pigs in both passive and active immunization.

PASSIVE IMMUNIZATION (ADMINISTRATION OF ANTIBODY).
Early studies demonstrated lysis of isolated adipocytes in vitro (34), and these antibodies were also effective in vivo (37). There were also unexpected effects: appetite, protein deposition, and food conversion efficiency all increased after treatment (82). There were, however, also side effects, including reduced food intake on the day of treatment and transient sedative effects lasting several hours. Activation of the immune system, along with depletion of serum complement, occurs rapidly after treatment and could explain these side effects. Subsequent studies were undertaken in sheep, pigs, chickens, and rabbits. In sheep, passive immunization against adipocyte plasma membranes produced modest effects, reducing both fat content and liveweight gain (78, 80). In rabbits, more dramatic effects were achieved 1 wk after treatment, but there was an ability to replete fat stores 2 mo later (27). The most profound effects have been achieved in pigs, where subcutaneous injections produced total fat depletion at injection sites that lasted for over 3 mo (59). Intraperitoneal injection of antiserum also produced a 30% decrease in back fat thickness, a 25% decrease in fat content of the forelimb, and an increase in muscle mass.

ACTIVE IMMUNIZATION.
Active immunization, using adipocyte plasma membranes as an immunogen, to provoke an autoimmune response against adipose tissues has been assessed in rats, sheep, and pigs. Although reductions in adipocyte cell numbers were achieved in rats, the effects were offset by compensatory increases in adipocyte volume, reducing the effect on adipose tissue mass. In sheep, one study failed to produce any significant effects, although a second study produced a decrease in fat and lean tissues. In contrast, in pigs, immunization produced significant decreases in body fat content.

MECHANISM OF ACTION OF ANTI-ADIPOSE ANTIBODIES.
An early study (34) demonstrated that antibodies could induce lysis of adipocytes in vitro solely in the presence of complement, whereas an in vivo study (37) involving cellular infiltration of adipose tissue suggested that cell-mediated responses might be responsible. A study (38) in complement-deficient rats clearly demonstrated that antibodies were completely ineffective in the absence of complement, demonstrating that complement activation is critical.

DEVELOPMENT OF AN ANTIOBESITY THERAPY.
It appears possible that this approach could be considered for clinical use to treat obesity. The antibody, however, would need to be a MAb, probably with absolute specificity for adipocytes. Approval of product licences for the treatment of obesity has arrived with the recognition that obesity is not simply a cosmetic problem but a considerable, and increasing, health risk to the population in general based on the strong association between obesity, diabetes, and cardiovascular disease. However, it is clear that antiobesity treatments will not be licensed for use if they only achieve weight loss. This must be accompanied by improvements in comorbidity factors such as blood lipid profiles and insulin sensitivity. There are also concerns that the mobilization of triglyceride in obese individuals could produce new problems, particularly in terms of cardiovascular disease and plaque formation.

To address some of these considerations, studies were conducted in the "cafeteria-fed" rat as a model of obesity. After consuming a high-fat diet and increasing their body weight by 50%, animals were treated with antisera to adipocytes. The response to treatment was a 10% decrease in body weight and a 30–40% reduction in body fat that lasted for at least 3 mo after treatment (33) (Fig. 7). There was also evidence of improvement in a factor associated with obesity, serum leptin, since concentrations were significantly decreased from the elevated levels present in untreated obese rats.

View larger version (12K): [in this window] [in a new window]   Fig. 7. Changes in body weight after treatment (arrows) with antibodies to adipocytes in rats fed a cafeteria diet (cafe). Diets were switched to a low-fat diet (chow), an intermediate-fat diet (fat), and then back to a high-fat diet (cafe), showing that the loss of weight was maintained independently of the diet. [From Ref. 89a.]

The search for such human antibodies has been considered via use of a human antibody library (111) in which suitable antibodies can be identified. A panel of over 100 different human single-chain Fv (scFv) antibodies binding human adipocyte plasma membranes have been isolated (31). Three of these scFvs were used in a subsequent study based on their additional cross-reaction with rat adipocytes. Each scFv was reformatted as a rat chimaeric IgG_2b, and the ability to induce lysis of rat epididymal adipocytes in vitro and the reduction of serum complement levels in vivo were determined. Each of these antibodies, both singly and in combination, was able to induce adipocyte lysis in vitro, and they were also effective in vivo, where they significantly reduced serum complement levels indicative of adipocyte lysis (25). Taken together, these results suggest that single MAbs could be used therapeutically and that massive adipocyte lysis occurring over several weeks is well tolerated in severely obese rodents, suggesting that at least some of the concerns regarding lipid mobilization during the weight loss period are unfounded.

Conclusions
This article has addressed the concepts of immune modulation of physiological processes in vivo and in vitro and the potential role of antibodies as models to understand physiological functions. Science has developed a sophisticated understanding of the complexities of both the immune system and physiological regulatory systems and how we might study and manipulate their interactions. Despite this, our understanding of these processes and interactions is incomplete.

For some physiological regulatory axes, we now understand some of the underlying mechanisms by which immune modulation may regulate specific processes. Enhancing antibodies against IGF-I clearly increase the available pool of the growth factor and decrease its rate of clearance from the circulation. Factors that contribute to these actions are related to the affinity of the antibodies and the binding site on the growth factor that is recognized by enhancing antibodies.

To develop immune modulation to its full potential, advances in understanding of the immune system and molecular physiological processes are required.

Immune modulation provides scientists with an alternative tool to study physiological processes in vivo. This constitutes an area of research that will provide greater understanding of fundamental physiology in the future; however, basic understanding of the underlying mechanisms must be improved before these benefits may be fully realized.

Received for publication March 31, 2008. Accepted for publication August 4, 2008.

REFERENCES

1. Allan GJ, Shand JH, Beattie J, Flint DJ. Identification of novel sites in the ovine growth hormone receptor involved in binding hormone and conferring species specificity. Eur J Biochem 261: 555–562, 1999.[Medline]
2. Arimura A, Smith WD, Schally AV. Blockade of the stress-induced decrease in blood GH by anti-somatostatin serum in rats. Endocrinology 98: 540–543, 1976.[Abstract/Free Full Text]
3. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy–review of a new approach. Pharmacol Rev 55: 241–269, 2003.[Abstract/Free Full Text]
4. Aston R, Cowden WB, Ada GL. Antibody-mediated enhancement of hormone activity. Mol Immunol 26: 435–446, 1989.[CrossRef][Medline]
5. Aston R, Holder AT, Ivanyi J, Bomford R. Enhancement of bovine growth hormone activity in vivo by monoclonal antibodies. Mol Immunol 24: 143–150, 1987.[CrossRef][Medline]
6. Aston R, Holder AT, Preece MA, Ivanyi J. Potentiation of the somatogenic and lactogenic activity of human growth hormone with monoclonal antibodies. J Endocrinol 110: 381–388, 1986.[Abstract/Free Full Text]
7. Bahouth SW, Wang H, Malbon CC. Immunological approaches for probing receptor structure and function. Trends Pharmacol Sci 12: 338–343, 1991.[CrossRef][Medline]
8. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzeimer disease. Nat Med 6: 916–919, 2000.[CrossRef][Web of Science][Medline]
9. Bass JJ, Gluckman PD, Fairclough RJ, Peterson AJ, Davis SR, Carter WD. Effect of nutrition and immunization against somatostatin on growth and insulin-like growth factors in sheep. J Endocrinol 112: 27–31, 1987.[Abstract/Free Full Text]
10. Bass JJ, Hodgkinson SC, Spencer GSG. Effects of immunisation against insulin-like growth factors. In: Vaccines in Agriculture: Immunological Applications to Animal Health and Production, edited by Wood PR, Willadsen P, Vercoe JE, Hoskinson RM, Demeyer D. Melbourne: CSIRO, 1994, p. 107–112.
11. Beauloye V, Muaku SM, Lause P, Portetelle D, Renaville R, Robert AR, Ketelslegers JM, Maiter D. Monoclonal antibodies to growth hormone (GH) prolong liver GH binding and GH-induced IGF/IGFBP-3 synthesis. Am J Physiol Endocrinol Metab 277: E308–E315, 1999.[Abstract/Free Full Text]
12. Beattie J, Fawcett HA, Flint DJ. The use of multiple-pin peptide synthesis in an analysis of the continuous epitopes recognised by various anti-(recombinant bovine growth hormone) sera. Comparison with predicted regions of immunogenicity and location within the three-dimensional structure of the molecule. Eur J Biochem 210: 59–66, 1992.[Medline]
13. Beattie J, Holder AT. Location of an epitope defined by an enhancing monoclonal antibody to growth hormone: some structural details and biological implications. Mol Endocrinol 8: 1103–1110, 1994.[Abstract/Free Full Text]
14. Beattie J, Shand JH, Flint DJ. An immobilised peptide array identifies antibodies to a discontinuous epitope in the extracellular domain of the bovine growth hormone receptor. Eur J Biochem 239: 479–486, 1996.[Medline]
15. Beh KJ, Blattman AN. The major histocompatibility complex system of vertebrates. In: Vaccines in Agriculture: Immunological Applications to Animal Health and Production, edited by Wood PR, Willadsen P, Vercoe JE, Hoskinson RM, Demeyer D. Melbourne: CSIRO, 1994, p. 37–48.
16. Chamat S, Hoebeke J, Emorine L, Guillet J, Strosberg AD. The immune response towards β-adrenergic ligands and their receptors. VI. Idiotypy of monoclonal anti-alprenolol antibodies. J Immunol 136: 3805–3811, 1986.[Abstract]
17. Chamat S, Hoebeke J, Strosberg AD. Monoclonal antibodies specific for β-adrenergic ligands. J Immunol 133: 1547–1552, 1984.[Medline]
18. Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 17: 780–783, 1999.[CrossRef][Web of Science][Medline]
19. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 17: 568–572, 1999.[CrossRef][Web of Science][Medline]
20. Clark R, Olson K, Fuh G, Marian M, Mortensen D, Teshima G, Chang S, Chu H, Mukku V, Canova-Davis E, Somers T, Cronin M, Winkler M, Wells JA. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 271: 21969–21977, 1996.[Abstract/Free Full Text]
21. Clark RG, Mortensen DL, Carlsson LM, Spencer SA, McKay P, Mulkerrin M, Moore J, Cunningham BC. Recombinant human growth hormone (GH)-binding protein enhances the growth-promoting activity of human GH in the rat. Endocrinology 137: 4308–4315, 1996.[Abstract]
22. Coy DH, Murphy WA, Sueiras-Diaz J, Coy EJ, Lance VA. Structure activity studies on the N-terminal region of growth hormone releasing factor. J Med Chem 28: 181–185, 1985.[CrossRef][Medline]
23. Dalum I, Butler DM, Jensen MR, Hindersson P, Steinaa L, Waterston AM, Grell SN, Feldmann M, Elsner HI, Mouritsen S. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 17: 666–669, 1999.[CrossRef][Web of Science][Medline]
24. De Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255: 306–312, 1992.[Abstract/Free Full Text]
25. Dickinson K, North TJ, Telford G, Smith SE, Edwards BM, Main SH, Field R, Hatton D, Vaughan TJ, Flint DJ, Jones RB. Antibody-induced lysis of isolated rat epididymal adipocytes and complement activation in vivo. Obes Res 10: 122–127, 2002.[Medline]
26. Dowsett KF, Tshweng U, Knott LM, Jackson AE, Trigg TE. Immunocastration of colts and immunospeying of fillies. Immunol Cell Biol 71: 501–508, 1993.
27. Dulor JP, Reyne Y, Nougues J. In vivo effects of treatment with antibodies to adipocyte plasma membranes in the rabbit. Reprod Nutr Dev 30: 49–58, 1990.[Medline]
28. Dunshea FR, Colantoni C, Howard K, McCauley I, Jackson P, Long KA, Lopaticki S, Nugent EA, Simons JA, Walker J, Hennessy DP. Vaccination of boars with a GnRH vaccine (Improvac) eliminates boar taint in increases growth performance. J Anim Sci 79: 2524–2535, 2001.[Abstract/Free Full Text]
29. Dusanter-Fourt I, Djiane J, Houdebine LM, Kelly PA. In vivo lactogenic effects of anti prolactin receptor antibodies in pseudopregnant rabbits. Life Sci 32: 407–412, 1983.[Medline]
30. Dusanter-Fourt I, Djiane J, Kelly PA, Houdebine LM, Teyssot B. Differential biological activities between mono- and bivalent fragments of anti-prolactin receptor antibodies. Endocrinology 114: 1021–1027, 1984.[Abstract/Free Full Text]
31. Edwards BM, Main SH, Cantone KL, Smith SD, Warford A, Vaughan TJ. Isolation and tissue profiles of a large panel of phage antibodies binding to the human adipocyte cell surface. J Immunol Methods 245: 67–78, 2000.[Medline]
32. Farmer C, Petitclerc D, Pelletier G, Gaudreau P, Brazeau P. Carcass composition and resistance to fasting in neonatal piglets born of sows immunized against somatostatin and/or receiving growth hormone-releasing factor injections during gestation. Biol Neonate 61: 110–117, 1992.[Medline]
33. Flint DJ. Effects of antibodies to adipocytes on body weight, food intake, and adipose tissue cellularity in obese rats. Biochem Biophys Res Commun 252: 263–268, 1998.[Medline]
34. Flint DJ, Coggrave H, Futter CE, Gardner MJ, Clarke TJ. Stimulatory and cytotoxic effects of an antiserum to adipocyte plasma membranes on adipose tissue metabolism in vitro and in vivo. Int J Obes 10: 69–77, 1986.[Web of Science][Medline]
35. Flint DJ, Tonner E, Beattie J, Panton D. Investigation of the mechanism of action of growth hormone in stimulating lactation in the rat. J Endocrinol 134: 377–383, 1992.[Abstract/Free Full Text]
36. Forbes K, Westwood M. The IGF axis and placental function. A mini review. Horm Res 69: 129–137, 2008.[CrossRef][Medline]
37. Futter CE, Flint DJ. Long-term reduction of adiposity in rats after passive immunization with antibodies to rat fat cell plasma membranes. In: Recent Advances in Obesity Research V, edited by Berry EM. London: Libbey, 1987, p. 181–185.
38. Futter CE, Panton D, Kestin S, Flint DJ. Mechanism of action of cytotoxic antibodies to adipocytes on adipose tissue, liver and food intake in the rat. Int J Obes Relat Metab Disord 16: 615–622, 1992.[Medline]
39. Guillet JG, Chamat S, Hoebeke J, Strosberg AD. Production and detection of monoclonal anti-idiotype antibodies directed against a monoclonal anti-β-adrenergic ligand antibody. J Immunol Methods 74: 163–171, 1984.[Medline]
40. Guillet JG, Kaveri SV, Durieu O, Delavier C, Hoebeke J, Strosberg AD. β-Adrenergic agonist activity of a monoclonal anti-idiotypic antibody. Proc Natl Acad Sci USA 82: 1781–1784, 1985.[Abstract/Free Full Text]
41. Guillet JG, Lengagne R, Magnusson Y, Tate K, Strosberg AD, Hoebeke J. Induction of a pharmacologically active clonotypic B cell response directed to an immunogenic region of the human β₂-adrenergic receptor. J Clin Exper Immunol 89: 461–467, 1992.
42. Hayden MS, Gilliland LK, Ledbetter JA. Antibody engineering. Curr Opin Immunol 9: 201–212, 1997.[CrossRef][Web of Science][Medline]
43. Heusser C, Jardieu P. Therapuetic potential of anti-IgE antibodies. Curr Opin Immunol 9: 805–814, 1997.[CrossRef][Web of Science][Medline]
44. Hill RA, Dye S, Sheldrick EL, Flick-Smith HC, Pell JM. Regulation of plasma clearance and tissue distribution of insulin-like growth factor-1 (IGF-1) by an IGF-1 enhancing antibody. J Endocrinol 144, Suppl: P63, 1995.
45. Hill RA, Flick-Smith FC, Dye S, Pell JM. Actions of an IGF-1-enhancing antibody on IGF-1 pharmacokinetics and tissue distribution: increased IGF-1 bioavailability. J Endocrinol 152: 123–130, 1997.[Abstract/Free Full Text]
47. Hill RA, Gazzola C, Herd RM, Oddy VH. An insulin-like growth factor-1 based vaccine changes body composition in Angus steers. Proc Nutr Soc Aust 22: 176, 1998.
48. Hill RA, Hoey AJ, Sillence MN. Functional activity of antibodies at the bovine β₂-adrenoceptor. J Anim Sci 76: 1651–1661, 1998.[Abstract/Free Full Text]
49. Hill RA, Pell JM. Regulation of insulin-like growth factor 1 (IGF-1) bioactivity in vivo: further characterisation of an IGF-1-enhancing antibody. Endocrinology 139: 1278–1287, 1998.[Abstract/Free Full Text]
50. Hill RA, Smith NN, Holmes MA. An insulin-like growth factor-1 (IGF-1) based vaccine improves growth rate in steers. In: Animal Production in Australia. Armidale, Australia: Univ. of New England, 1998, p. 321.
51. Holder AT, Aston R, Preece MA, Ivanyi J. Monoclonal antibody-mediated enhancement of growth hormone activity in vivo. J Endocrinol 107: R9–R12, 1985.[Abstract/Free Full Text]
52. Hoskinson RM, Djura P, Welch RJ, Harrison BE, Brown GH, Donnelly JB, Jones MR. Failure of antisomatostatin antibodies to stimulate the growth of crossbred lambs. Aust J Exper Agric 28: 161–165, 1988.
53. Hoskinson RM, Rigby RDG, Mattner PE, Huynh VL, D'Occhio MJ, Neish A, Trigg TE, Moss BA, Lindsay MJ, Coleman GD. Vaxtreate: an anti-reproductive vaccine for cattle. Aust J Biotechnol 4: 166–170, 1990.[Medline]
54. Hudson PJ. Recombinant antibody constructs in cancer therapy. Curr Opin Immunol 11: 548–557, 1999.[CrossRef][Web of Science][Medline]
55. Huls GA, Heijnen IA, Cuomo ME, Koningsberger JC, Wiegman L, Boel E, van der Vuurst de Vries AR, Loyson SA, Helfrich W, van Berge Henegouwen GP, van Meijer M, de Kruif J, Logtenberg T. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol 17: 276–281, 1999.[CrossRef][Web of Science][Medline]
56. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3–34, 1995.[Abstract/Free Full Text]
57. Kabir S. The current status of Helicobacter pylori vaccines: a review. Helicobacter 12: 89–102, 2007.[Medline]
58. Kerr DE, Laarveld B, Manns JG. Effects of passive immunization of growing guinea-pigs with an insulin-like growth factor-I monoclonal antibody. J Endocrinol 124: 403–415, 1990.[Abstract/Free Full Text]
59. Kestin S, Kennedy R, Tonner E, Kiernan M, Cryer A, Griffin H, Butterwith S, Rhind S, Flint D. Decreased fat content and increased lean in pigs treated with antibodies to adipocyte plasma membranes. J Anim Sci 71: 1486–1494, 1993.[Abstract]
60. Kim YH, Kim YS. Effects of active immunization against clenbuterol on the growth-promoting effect of clenbuterol in rats. J Anim Sci 75: 446–453, 1997.[Abstract/Free Full Text]
61. Kirkwood RN, Korchinski RS, Thacker PA, Laarveld B. Observations on the influence of active immunization against somatostatin on the reproductive performance of sheep and pigs. J Reprod Immunol 17: 229–238, 1990.[Medline]
62. Koea JB, Gallaher BW, Breier BH, Douglas RG, Hodgkinson S, Shaw JHF, Gluckman PD. Passive immunisation against circulating insulin-like growth factor-I (IGF-I) increases protein catabolism in lambs: evidence for a physiological role for circulating IGF-I. J Endocrinol 135: 279–284, 1992.[Abstract/Free Full Text]
63. Laarveld B, Chaplin RK, Kerr DE. Somatostatin immunization and growth of lambs. Can J Anim Sci 66: 77–83, 1986.
64. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144–2148, 2000.[CrossRef][Web of Science][Medline]
65. Leibovich H, Gertler A, Bazer FW, Gootwine E. Active immunization of ewes against ovine placental lactogen increases birth weight of lambs and milk production with no adverse effect on conception rate. Anim Reprod Sci 64: 33–47, 2000.[CrossRef][Web of Science][Medline]
66. Limas CJ, Limas C. Beta-adrenoceptor antibodies and genetics in dilated cardiomyopathy–an overview and review. Eur Heart J 12, Suppl D: 175–177, 1991.[Abstract/Free Full Text]
67. Lu B, Couraud P, Schmutz A, Strosberg AD. The internal image of catecholamines: expression and regulation of a functional network. Ann NY Acad Sci 418: 240–247, 1984.
68. Magnusson Y, Hoyer S, Lengagne R, Chapot MP, Guillet JG, Hjalmarson A, Strosberg AD, Hoebeke J. Antigenic analysis of the second extra-cellular loop of the human β-adrenergic receptors. Clin Exper Immunol 78: 42–48, 1989.[Web of Science][Medline]
69. Magnusson Y, Marullo S, Hoyer S, Waagstein F, Anderrson B, Vahine A, Guillet J, Strosberg AD, Hjalmarson A, Hoebeke J. Mapping of a functional autoimmune epitope on the β₁-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest 86: 1658–1663, 1990.[Web of Science][Medline]
70. Magnusson Y, Wallukat G, Guillet J, Hjalmarson A, Hoebeke J. Functional analysis of rabbit anti-peptide antibodies which mimic autoantibodies against the β₁-adrenergic receptor in patients with idioipathic dilated cardiomyopathy. J Autoimmun 4: 893–905, 1991.[Medline]
71. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation 89: 2760–2767, 1994.[Abstract/Free Full Text]
72. Manes S, Kremer L, Albar JP, Mark C, Llopis R, Martinez-AC. Functional epitope mapping of insulin-like growth factor I (IGF-I) by anti-IGF-I monoclonal antibodies. Endocrinology 138: 905–915, 1997.[Abstract/Free Full Text]
73. Manes S, Kremer L, Vangbo B, Lopez A, Gomez-Mouton C, Peiro E, Albar JP, Mendel-Hartvig IB, Llopis R, Martinez C. Physical mapping of human insulin-like growth factor-I using specific monoclonal antibodies. J Endocrinol 154: 293–302, 1997.[Abstract/Free Full Text]
74. Massart S, Ban AM, Renaville R, Van Eenaeme C, Sneyers M, Falaki M, Istasse L, Clinquart A, Devolder A, Burny A, Portetelle D. Characterization of growth hormone-binding protein in cattle plasma: prolactin-binding activity and 24-hour profile. Domest Anim Endocrinol 13: 47–57, 1996.[Medline]
75. Massart S, Maiter D, Portetelle D, Adam E, Renaville R, Ketelslegers JM. Monoclonal antibodies to bovine growth hormone potentiate hormonal activity in vivo by enhancing growth hormone binding to hepatic somatogenic receptors. J Endocrinol 139: 383–393, 1993.[Abstract/Free Full Text]
76. Meloen RH. Basic aspects of immunomodulation through active immunisation. Livest Prod Sci 42: 135–145, 1995.
77. Mockridge JW, Aston R, Morrell DJ, Holder AT. Cross-linked growth hormone dimers have enhanced biological activity. Eur J Endocrinol 138: 449–459, 1998.[Abstract]
78. Moloney AP, Allen P. Growth and weights of abdominal and carcass fat in sheep immunized against adipose cell membranes. Proc Nutr Soc 48: 14A, 1989.
79. Nahmias C, Strosberg AD, Emorine LJ. The immune response toward β-adrenergic ligands and their receptors. VIII. Extensive diversity of V_H and V_L genes encoding anti-alprenolol antibodies. J Immunol 140: 1304–1311, 1988.[Abstract]
80. Nassar AH, Hu CY. Growth and carcass characteristics of lambs passively immunised with antibodies developed against ovine adipocyte plasma membranes. J Anim Sci 69: 578–586, 1991.[Abstract]
81. Palmer RM, Loveridge N, Thomson BM, Mackie SC, Tonner E, Flint DJ. Effects of a polyclonal antiserum to rat growth hormone on circulating insulin-like growth factor (IGF)-I and IGF-binding protein concentrations and the growth of muscle and bone. J Endocrinol 142: 85–91, 1994.[Abstract/Free Full Text]
82. Panton D, Futter CE, Kestin S, Flint DJ. Increased growth and protein deposition in rats treated with antibodies to adipocytes. Am J Physiol Endocrinol Metab 258: E985–E989, 1990.[Abstract/Free Full Text]
83. Pell JM, Aston R. Principles of immunomodulation. Livest Prod Sci 42: 123–133, 1995.[CrossRef]
84. Pell JM, Flick-Smith HC, Dye S, Hill RA. Further characterisation of an IGF-1 enhancing antibody: actions on IGF-induced hypoglycaemia and interaction with the analogue LR3IGF-1. Prog Growth Factor Res 6: 367–375, 1995.[CrossRef][Medline]
85. Pell JM, Flick-Smith HC, Stewart CEH, Hill RA. Peptide mimics for a major binding site on IGF-1 for an IGF-1-enhancing antibody. J Endocrinol 151, Suppl: P32, 1996.
86. Pell JM, Hill RA, Stewart CEH, Weston CR, Flick-Smith HC. Enhancement of IGF-I activity by novel antisera: potential structure/function interactions. Endocrinology 141: 741–751, 2000.[Abstract/Free Full Text]
87. Pell JM, James S. Immuno-enhancement and -inhibition of GH-releasing factor by site-directed and anti peptide antibodies in vivo and in vitro. J Endocrinol 146: 535–541, 1995.[Abstract/Free Full Text]
88. Pell JM, Johnson ID, Puller RA, Morrell DJ, Hart IC, Holder AT, Aston R. Potentiation of growth hormone activity in sheep using monoclonal antibodies. J Endocrinol 120: R15–R18, 1989.[Abstract/Free Full Text]
89. Roitt IM, Brostoff J, Male DK. Immunology. London: Mosby, 1993.
89. Scanes CG. Biology of Growth of Domestic Animals. Ames, IA: Iowa State Press, 2003.
90. Scarth JP. Modulation of the growth hormone-insulin-like growth factor (GH-IGF) axis by pharmaceutical, nutraceutical and environmental xenobiotics: an emerging role for xenobiotic-metabolizing enzymes and the transcription factors regulating their expression. A review. Xenobiotica 36: 119–218, 2006.[Medline]
91. Scott AM, Welt S. Antibody-based immunological therapies. Curr Opin Immunol 9: 717–722, 1997.[CrossRef][Web of Science][Medline]
92. Smith NN, Hill RA. Binding characterisation of anti-insulin-like growth factor-1 (IGF-1) antibodies raised in cattle and sheep. Proc Endocr Soc Aust 42: 73, 1999.
93. Smith NN, Hill RA, Pegg GG, Pell JM. Passive immunisation with anti-IGF-1 antibodies increases feed intake during nutritional restriction. Asian Aust J Anim Sci 13, Suppl C: 154, 2000.
94. Spencer GS, Harvey S, Audsley AR, Hallett KG, Kestin S. The effect of immunization against somatostatin on growth rates and growth hormone secretion in the chicken. Comp Biochem Physiol A 85: 553–556, 1986.
95. Spencer GSG. Effect of immunisation against somatostatin on growth rate of lambs. In: Manipulation of Growth in Farm Animals, edited by Roche JF, O'Callaghan D. Hingham, MA: Nijhoff, 1984, p. 122–136.
96. Spencer GSG, Garssen GJ, Bergström PL. A novel approach to growth promotion using auto-immunisation against somatostatin. II. Effects on appetite, carcass composition and food utilisation in lambs. Livest Prod Sci 10: 469–477, 1983.
97. Spencer GSG, Garssen GJ, Hart IC. A novel approach to growth promotion using auto-immunisation against somatostatin. I. Effects on growth and hormone levels in lambs. Livest Prod Sci 10: 25–37, 1983.
98. Spencer GSG, Hodgkinson SC, Bass JJ. Passive immunisation against insulin-like growth factor-I does not inhibit growth hormone-stimulated growth in dwarf rats. Endocrinology 128: 2103–2109, 1991.[Abstract/Free Full Text]
99. Spencer GSG, Williamson ED. Increased growth in lambs following auto-immunization against somatostatin. Anim Prod 32: 376, 1981.
100. Stewart CE, Bates PC, Calder TA, Woodall SM, Pell JM. Potentiation of insulin-like growth factor-I (IGF-I) activity by an antibody: supportive evidence for enhancement of IGF-I bioavailability in vivo by IGF binding proteins. Endocrinology 133: 1462–1465, 1993.[Abstract/Free Full Text]
101. Strosberg AD. Anti-idiotypic antibodies that interact with β-adrenergic catecholamine receptor. Methods Enzymol 178: 265–275, 1989.[Medline]
102. Strosberg AD. Functional modulation of β-adrenergic receptors by specific ligands and antibodies. In: Vaccines in Agriculture: Immunological Applications to Animal Health and Production, edited by Wood PR, Willadsen P, Vercoe JE, Hoskinson RM, Demeyer D. Melbourne: CSIRO, 1994, p. 123–135.
103. Strosberg AD, Chamat S, Guillet JG, Lavaud B, Emorine L, Hoebeke J. Idiotypy of catecholamine-binding proteins. Annales de l Institut Pasteur Immunologie 136C: 157–168, 1985.
104. Strosberg AD, Guillet JG, Chamat S, Hoebeke J. Recognition of physiological receptors by anti-idiotypic antibodies: molecular mimicry of the ligand or cross-reactivity. Curr Topics Microbiol Immunol 119: 91–110, 1985.[Medline]
105. Sun YX, Drane GL, Currey SD, Lehner ND, Gooden JM, Hoskinson RM, Wynn PC, McDowell GH. Immunization against somatotropin release inhibiting factor improves digestibility of food, growth and wool production of crossbred lambs. Aust J Agric Res 41: 401–411, 1990.
106. Sun YX, Sinclair SE, Wynn PC, McDowell GH. Immunization against somatotropin release inhibiting factor increases milk yield in ewes. Aust J Agric Res 41: 393–400, 1990.
107. Tans C, Dubois F, Zhong ZD, Jadot M, Wattiaux R, Wattiaux-De Coninck S. Uptake by rat liver of bovine growth hormone free or bound to a monoclonal antibody. Biol Cell 82: 45–49, 1994.[CrossRef][Web of Science][Medline]
108. Taylor PC, Williams RO, Maini RN. Immunotherapy for rheumatoid arthritis. Curr Opin Immunol 13: 611–616, 2001.[CrossRef][Medline]
109. Theveniau MA, Raymond JR, Rougon G. Antipeptide antibodies to the β₂-adrenergic receptor confirm the extracellular orientation of the amino-terminus and the putative first extrcellular loop. J Membr Biol 111: 141–153, 1989.[Medline]
110. Vaiseman N, Nissim A, Klapper LN, Tirosh B, Yarden Y, Sela M. Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. Immunol Lett 75: 61–67, 2000.[CrossRef][Web of Science][Medline]
111. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14: 309–314, 1996.[CrossRef][Web of Science][Medline]
112. Wallukat G, Nissen E, Morwinski R, Muller J. Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy. Herz 25: 261–266, 2000.[CrossRef][Web of Science][Medline]
113. Wang BS, Lumanglas AL, Szewczyk E, McWilliams W, Loullis CC, Hart IC. A proposed mechanism of action of a growth hormone-specific monoclonal antibody in the enhancement of hormonal activity. Mol Immunol 29: 313–317, 1992.[Medline]
114. Wang HS, Chard T. The role of insulin-like growth factor-I and insulin-like growth factor-binding protein-1 in the control of human fetal growth. J Endocrinol 132: 11–19, 1992.[Abstract/Free Full Text]
115. Wynn PC, Behrendt R, Jones MR, Rigby RDG, Bassett JR, Hoskinson RM. Immuno-modulation of hormones controlling growth. Aust J Agric Res 45: 1091–1109, 1994.[CrossRef]
116. Wynn PC, Behrendt R, Pattison ST, Jones MR, Shahneh A, Yacoub C, Sheehy PA, Rigby RDG, Bassett JR, Hoskinson RM. Immunomodulation of hormones of the hypothalamic-pituitary-adrenal axis and animal productivity. In: Vaccines in Agriculture: Immunological Applications to Animal Health and Production, edited by Wood PR, Willadsen P, Vercoe JE, Hoskinson RM, Demeyer D. Melbourne: CSIRO, 1994, p. 114–122.
117. Wynn PC, Shahneh AZ, Rigby RDG, Behrendt R, Giles LR, Gooden JM, Jones MR. Physiological consequences of the induction of auto-immunity to adrenocorticotropin (ACTH). Livest Prod Sci 42: 247–254, 1995.[CrossRef]
118. Zeitlin L, Cone RA, Moench TR, Whaley KJ. Preventing infectious disease with passive immunization. Microbes Infect 2: 701–708, 2000.[CrossRef][Web of Science][Medline]

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hill, R. A. Articles by Pell, J. M. Search for Related Content PubMed PubMed Citation Articles by Hill, R. A. Articles by Pell, J. M.